Patorno E, et al. - This study was performed to assess the cardiovascular safety of canagliflozin (a sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus) in direct comparisons with DPP-4 inhibitors (DPP-4i), GLP-1 receptor agonists (GLP-1RA), or sulfonylureas, as used in routine practice. In direct comparisons with three different classes of non-gliflozin diabetes treatment alternatives as used in routine care, canagliflozin was found to be correlated with a lower risk of heart failure admission to hospital and with a similar risk of myocardial infarction or stroke.